Previously recorded as Huya Bioscience International, LLC (to 2021)
17 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
6
Ending by 2030
Nov 2030
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2037 · High confidence
Also notable
Ends Jan 2040 · High confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Jan 2031 · High confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends May 2042 · High confidence
Combination Therapies of Hdac Inhibitors and PD-1 Inhibitors
US 10,385,130
The most cited patent in this portfolio, cited by 45 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Sulcardine Salts
US 11,426,382
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Sulcardine Administration for Treatment of Acute Atrial Fibrillation
US 11,364,223
Granted 2022. Computed term ends 2030. A terminal disclaimer caps this term to an earlier patent's.
Combination Therapies of Hdac Inhibitors and PD-L1 Inhibitors
US 10,385,131
Cited by 11 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2037.
Slow Infusion of Sulcardine and Its Salts
US 8,637,566
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2031.
Treatment of Atrial Fibrillation
US 8,541,464
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2030.
Sulcardine Administration for Treatment of Acute Atrial Fibrillation
US 11,813,245
Granted 2023. Computed term ends 2030. A terminal disclaimer caps this term to an earlier patent's.
SHP2 Inhibitor Monotherapy and Uses Thereof
US 12,390,469
Granted 2025. Too new for citation comparison; protection runs to 2042.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 20, 2027
- 1 fee due May 14, 2027The maintenance fee for Sulcardine Administration for Treatment of Acute Atrial Fibrillation (US 11,813,245) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Sulcardine Administration for Treatment of Acute Atrial Fibrillation (US 11,883,380) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Sulcardine Salts | 3 in force | to Aug 2041 |
| Combination Therapies of Hdac Inhibitors and PD-1 Inhibitors | 3 in force | to May 2037 |
| Sulcardine Administration for Treatment of Acute Atrial Fibrillation (2019) | 3 in force | to Nov 2030 |
| Combination Therapies of Hdac Inhibitors and PD-L1 Inhibitors | 2 in force | to May 2037 |
| Sulcardine Administration for Treatment of Acute Atrial Fibrillation (2021) | 2 in force | to Nov 2030 |
| SHP2 Inhibitor Monotherapy and Uses Thereof | 1 in force | to May 2042 |
| Slow Infusion of Sulcardine and Its Salts | 1 in force | to Jan 2031 |
| Treatment of Atrial Fibrillation | 1 in force | to Nov 2030 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,541,464 | Treatment of Atrial Fibrillation In force · High confidence | In force | High confidence | |
| US 11,364,223 | Sulcardine Administration for Treatment of Acute Atrial Fibrillation In force · High confidence | In force | High confidence | |
| US 11,813,245 | Sulcardine Administration for Treatment of Acute Atrial Fibrillation In force · High confidence | In force | High confidence | |
| US 11,883,380 | Sulcardine Administration for Treatment of Acute Atrial Fibrillation In force · High confidence | In force | High confidence | |
| US 12,357,611 | Sulcardine Administration for Treatment of Acute Atrial Fibrillation In force · High confidence | In force | High confidence | |
| US 12,465,587 | Sulcardine Administration for Treatment of Acute Atrial Fibrillation In force · High confidence | In force | High confidence | |
| US 8,637,566 | Slow Infusion of Sulcardine and Its Salts In force · High confidence | In force | High confidence | |
| US 10,287,353 | Combination Therapies of Hdac Inhibitors and PD-1 Inhibitors In force · High confidence | In force | High confidence | |
| US 10,385,130 | Combination Therapies of Hdac Inhibitors and PD-1 Inhibitors In force · High confidence | In force | High confidence | |
| US 10,385,131 | Combination Therapies of Hdac Inhibitors and PD-L1 Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 17: 16 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.